LSH.ASX
Lifespot Health rebrands to InhaleRx, pushes development of Medihale inhaler
Australian medicinal cannabis device company Lifespot Health (ASX: LSH) has officially changed its name to InhaleRx (ASX: IRX), with the change to take effect on Wednesday. The new moniker has been termed a “natural evolution” for the company, which announced a strategic change of direction last year from promoting skin cancer screening technology to the […]
Lifespot Health reveals new R&D strategy amid board shake-up
Medical cannabis device developer Lifespot Health (ASX: LSH) has announced a revised research and development strategy prioritising US Food and Drug Administration (FDA) approval of its Medihale cannabinoid inhaler system. The news follows several changes to the company’s board including the most recent appointment of a new chairman, Sean Williams. Lifespot today revealed its chosen […]
Lifespot Health appoints cannabis specialists to board of directors
Australian medicinal cannabis device company Lifespot Health (ASX: LSH) has appointed two non-executive directors to its board to help execute a strategy of delivering innovative medication systems and therapies to market. Cannabinoid specialists Dr Andrew Saich and Darryl Davies have a wealth of combined industry experience and are believed to be well-qualified to drive the […]
Lifespot Health appoints Canadian advisor to take medical cannabis technology to the world stage
Medical cannabis device developer Lifespot Health (ASX: LSH) has appointed Canadian investment fund Ela Capital as its corporate advisor to assist with the commercialisation of its technologies in the global cannabis market. Toronto-based Ela Capital became a major shareholder of Lifespot at the start of the year after investing close to $800,000 in a capital […]